HER 2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization.

Simple item page
dc.contributor.authorShirsat, Hemlata S
dc.contributor.authorEpari, Sridhar
dc.contributor.authorShet, Tanuja
dc.contributor.authorBagal, Rajani
dc.contributor.authorHawaldar, Rohini
dc.contributor.authorDesai, Sangeeta B
dc.date.accessioned2012-10-17T04:29:53Z
dc.date.available2012-10-17T04:29:53Z
dc.date.issued2012-04
dc.description.abstractIntroduction : HER2/neu gene status in breast cancers can be evaluated by targeting protein and gene - immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH). Recent studies have shown chromogenic in-situ hybridization (CISH) as a relatively cheaper alternative. Materials and Methods : Forty-three nonconsecutive, randomly selected primary invasive breast cancer cases were evaluated for c-erbB-2 (HER2 protein) by IHC and gene amplification by FISH and CISH. Results of each of the same were compared. Results : CISH showed approximately 90% and 100% concordance for IHC negative and positive cases, respectively; while approximately 94.4% and 91% concordance with FISH amplified and non-amplified cases, respectively. Conclusion : This study showed feasibility of incorporation of CISH as a low cost option in routine management of breast carcinoma in the Indian setting. Secondly, reconfirmation of IHC negative and positive cases can be done by CISH.en_US
dc.identifier.citationShirsat Hemlata S, Epari Sridhar, Shet Tanuja, Bagal Rajani, Hawaldar Rohini, Desai Sangeeta B. HER 2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization. Indian Journal of Pathology & Microbiology. 2012 Apr-Jun 55(2): 175-179.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/142216
dc.language.isoenen_US
dc.source.urihttps://www.ijpmonline.org/article.asp?issn=0377-4929;year=2012;volume=55;issue=2;spage=175;epage=179;aulast=Shirsaten_US
dc.subjectBreast canceren_US
dc.subjectchromogenic in-situ hybridizationen_US
dc.subjectfluorescence in-situ hybridizationen_US
dc.subjectHER2/neuen_US
dc.subjectimmunohistochemistryen_US
dc.subject.meshBreast Neoplasms --diagnosis
dc.subject.meshBreast Neoplasms --pathology
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunohistochemistry --economics
dc.subject.meshImmunohistochemistry --methods
dc.subject.meshIn Situ Hybridization --economics
dc.subject.meshIn Situ Hybridization --methods
dc.subject.meshIndia
dc.subject.meshMolecular Diagnostic Techniques --economics
dc.subject.meshMolecular Diagnostic Techniques --methods
dc.subject.meshPathology --economics
dc.subject.meshPathology --methods
dc.subject.meshReceptor, erbB-2 --biosynthesis
dc.titleHER 2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijpm2012v55n2p175.pdf
Size:
3.25 MB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Pathology & Microbiology